Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Seres Therapeutics, Inc.MCRB · Entity 7191 | See Remarks | February 15, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Seres Therapeutics, Inc.
Report date February 15, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,557 |
Ending reported balance
After 2026-02-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-15 · Exercise / conversion · Acquired 231 · Balance 8,632 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Row 2 · 2026-02-15 · Sale · Disposed 75 · Balance 8,557 F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 531 |
Reported balance
After 2026-02-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-15 · Exercise / conversion · Disposed 133 · Balance 531 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 780 |
Reported balance
After 2026-02-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-15 · Exercise / conversion · Disposed 98 · Balance 780 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
F3: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
F4: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2026 Filed Feb 18, 2026 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 98 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-057157 · ownership.xml · derivative · entry 4 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 780 Underlying: Common Stock · 98 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 133 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-057157 · ownership.xml · derivative · entry 3 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 531 Underlying: Common Stock · 133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 75 | $8.47 | $635.25 |
DisclosureSEC source: 0001193125-26-057157 · ownership.xml · nonDerivative · entry 2 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,557 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-057157 · ownership.xml · nonDerivative · entry 1 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| November 15, 2025 Filed Nov 18, 2025 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 98 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-286236 · ownership.xml · derivative · entry 7 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 878 Underlying: Common Stock · 98 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F5 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| November 15, 2025 Filed Nov 18, 2025 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 132 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-286236 · ownership.xml · derivative · entry 6 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 664 Underlying: Common Stock · 132 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| November 15, 2025 Filed Nov 18, 2025 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 3,998 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-286236 · ownership.xml · derivative · entry 5 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,998 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The RSUs vested in a single installment on November 15, 2025. The RSUs have no expiration date. F3 · derivative.expiration_date: The RSUs vested in a single installment on November 15, 2025. The RSUs have no expiration date. Read SEC document |
| November 15, 2025 Filed Nov 18, 2025 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 1,042 | $17.30 | $18,026.60 |
DisclosureSEC source: 0001193125-25-286236 · ownership.xml · nonDerivative · entry 4 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,401 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. Read SEC document |
| November 15, 2025 Filed Nov 18, 2025 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 98 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-286236 · ownership.xml · nonDerivative · entry 3 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| November 15, 2025 Filed Nov 18, 2025 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 132 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-286236 · ownership.xml · nonDerivative · entry 2 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| November 15, 2025 Filed Nov 18, 2025 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 3,998 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-286236 · ownership.xml · nonDerivative · entry 1 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| September 26, 2025 Filed Sep 30, 2025 20:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantRestricted Stock Units · Derivative | 3,998 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-225105 · ownership.xml · derivative · entry 1 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,998 Underlying: Common Stock · 3,998 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The RSUs will vest in a single installment on November 15, 2025, subject to the Reporting Person's satisfaction of the terms contemplated in the award agreement.The RSUs have no expiration date. F2 · derivative.expiration_date: The RSUs will vest in a single installment on November 15, 2025, subject to the Reporting Person's satisfaction of the terms contemplated in the award agreement.The RSUs have no expiration date. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 20:06 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 59 | $16.65 | $982.35 |
DisclosureSEC source: 0001193125-25-183434 · ownership.xml · nonDerivative · entry 3 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,215 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:06 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 97 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-183434 · ownership.xml · derivative · entry 5 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 976 Underlying: Common Stock · 97 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:06 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 133 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-183434 · ownership.xml · derivative · entry 4 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 796 Underlying: Common Stock · 133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:06 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 97 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-183434 · ownership.xml · nonDerivative · entry 2 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:06 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 133 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-183434 · ownership.xml · nonDerivative · entry 1 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,177 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| May 16, 2025 Filed May 19, 2025 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 63 | $7.28 | $458.64 |
DisclosureSEC source: 0000950170-25-074328 · ownership.xml · nonDerivative · entry 3 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,044 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F2 · balance_after: Reflects a 1-for-20 reverse stock split effected on April 21, 2025. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 98 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-074328 · ownership.xml · derivative · entry 5 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,073 Underlying: Common Stock · 98 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F5 · derivative.expiration_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F2 · balance_after: Reflects a 1-for-20 reverse stock split effected on April 21, 2025. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 133 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-074328 · ownership.xml · derivative · entry 4 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 929 Underlying: Common Stock · 133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F2 · balance_after: Reflects a 1-for-20 reverse stock split effected on April 21, 2025. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 98 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-074328 · ownership.xml · nonDerivative · entry 2 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · balance_after: Reflects a 1-for-20 reverse stock split effected on April 21, 2025. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 133 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-074328 · ownership.xml · nonDerivative · entry 1 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · balance_after: Reflects a 1-for-20 reverse stock split effected on April 21, 2025. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 01:11 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 3,338 | $0.81 | $2,704.45 |
DisclosureSEC source: 0000950170-25-023584 · ownership.xml · nonDerivative · entry 3 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,536 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.81 to $0.832001, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 01:11 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 7,813 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-023584 · ownership.xml · derivative · entry 5 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,437 Underlying: Common Stock · 7,813 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F5 · derivative.expiration_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 01:11 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 2,657 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-023584 · ownership.xml · derivative · entry 4 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,250 Underlying: Common Stock · 2,657 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 01:11 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 7,813 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-023584 · ownership.xml · nonDerivative · entry 2 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 01:11 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 2,657 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-023584 · ownership.xml · nonDerivative · entry 1 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 21:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 650,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0000950170-25-017913 · ownership.xml · derivative · entry 1 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2035-02-06 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on February 7, 2026. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| November 18, 2024 Filed Nov 19, 2024 21:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 735 | $0.54 | $397.64 |
DisclosureSEC source: 0000950170-24-128613 · ownership.xml · nonDerivative · entry 2 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,404 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.5406 to $ 0.5638, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 21:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 2,656 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-128613 · ownership.xml · derivative · entry 3 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,907 Underlying: Common Stock · 2,656 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 21:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 2,656 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-128613 · ownership.xml · nonDerivative · entry 1 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| October 28, 2024 Filed Oct 29, 2024 22:23 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 2,983 | $0.69 | $2,058.57 |
DisclosureSEC source: 0000950170-24-118405 · ownership.xml · nonDerivative · entry 2 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,483 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 18, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F4 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.69 to $ 0.6934, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 27, 2024 Filed Oct 29, 2024 22:23 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 11,360 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-118405 · ownership.xml · derivative · entry 3 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,360 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. F1 · derivative.exercise_date: On February 3, 2023, the reporting person was granted an award of 22,721 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 11,361 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 11,360 RSUs vested and settled on October 27, 2024, the date that was eighteen months from the Initial Milestone Date. F2 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. Read SEC document |
| October 27, 2024 Filed Oct 29, 2024 22:23 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 11,360 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-118405 · ownership.xml · nonDerivative · entry 1 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On February 3, 2023, the reporting person was granted an award of 22,721 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 11,361 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 11,360 RSUs vested and settled on October 27, 2024, the date that was eighteen months from the Initial Milestone Date. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. Read SEC document |
| August 16, 2024 Filed Aug 19, 2024 21:36 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 728 | $0.84 | $611.52 |
DisclosureSEC source: 0000950170-24-098710 · ownership.xml · nonDerivative · entry 2 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,106 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.8414 to $ 0.8900, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:36 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 2,656 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-098710 · ownership.xml · derivative · entry 3 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,563 Underlying: Common Stock · 2,656 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:36 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 2,656 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-098710 · ownership.xml · nonDerivative · entry 1 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| August 05, 2024 Filed Aug 6, 2024 20:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 24,480 | $1.08 | $26,533.87 |
DisclosureSEC source: 0000950170-24-091832 · ownership.xml · nonDerivative · entry 2 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,178 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 28, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $1.08 to $1.1101, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2024 Filed Aug 6, 2024 20:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-091832 · ownership.xml · derivative · entry 3 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested and settled as to 100% of the restricted stock units on August 3, 2024. F4 · derivative.expiration_date: The restricted stock units vested and settled as to 100% of the restricted stock units on August 3, 2024. Read SEC document |
| August 03, 2024 Filed Aug 6, 2024 20:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 85,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-091832 · ownership.xml · nonDerivative · entry 1 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,658 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| May 15, 2024 Filed May 18, 2024 00:18 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 2,656 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062058 · ownership.xml · derivative · entry 3 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,219 Underlying: Common Stock · 2,656 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| May 15, 2024 Filed May 18, 2024 00:18 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 703 | $0.94 | $660.82 |
DisclosureSEC source: 0000950170-24-062058 · ownership.xml · nonDerivative · entry 2 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,658 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.94 to $0.943, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 15, 2024 Filed May 18, 2024 00:18 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 2,656 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-062058 · ownership.xml · nonDerivative · entry 1 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 16, 2024 Filed Feb 17, 2024 02:29 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 3,374 | $1.08 | $3,643.92 |
DisclosureSEC source: 0000950170-24-016694 · ownership.xml · nonDerivative · entry 2 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,705 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3 · price: The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.08 to $1.115, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 15, 2024 Filed Feb 17, 2024 02:29 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 10,625 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-016694 · ownership.xml · derivative · entry 6 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,875 Underlying: Common Stock · 10,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F7 · derivative.exercise_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F7 · derivative.expiration_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| February 15, 2024 Filed Feb 17, 2024 02:29 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 10,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-016694 · ownership.xml · nonDerivative · entry 1 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 02:29 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantRestricted Stock Units · Derivative | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-016694 · ownership.xml · derivative · entry 5 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 31,250 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F6 · derivative.exercise_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F6 · derivative.expiration_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 02:29 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 287,905 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0000950170-24-016694 · ownership.xml · derivative · entry 4 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 287,905 Underlying: Common Stock · 287,905 shares Expires 2034-02-13 F5 · derivative.exercise_date: The option will vest, if at all, in two substantially equal installments upon achievement of a 30-day trailing average public market closing price per share of the Issuer's common stock greater than or equal to $3.00 and $5.00, respectively. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 02:29 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 187,500 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0000950170-24-016694 · ownership.xml · derivative · entry 3 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2034-02-13 F4 · derivative.exercise_date: The option will vest as to 25% of the shares on February 14, 2025. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| October 30, 2023 Filed Nov 1, 2023 01:40 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 2,907 | $1.35 | $3,924.45 |
DisclosureSEC source: 0000899243-23-020079 · doc4.xml · nonDerivative · entry 2 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,454 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 18, 2023, solely with the intent to cover taxes in connection with the vesting of the RSUs. F3 · price: The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.3425 to $1.405, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.